Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors.

Journal of medicinal chemistry - 23 Apr 2020

Heppner David E, Günther Marcel, Wittlinger Florian, Laufer Stefan A, Eck Michael J

Abstract excerpt

Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in cancer therapy. Previous studies of trisubstituted imidazole inhibitors led to the serendipitous discovery of inhibitors that target the drug resistant EGFR(L858R/T790M/C797S) mutant with nanomolar potencies in a reversible binding mechanism. To dissect the molecular basis for their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Genetic Variation

Share to Imidazoles

Share to Mutation

Share to Protein Structure, Secondary

Share to Sf9 Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 32243152
DOI: 10.1021/acs.jmedchem.0c00200
PMCID: PMC7730863

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors.PMID 32243152Read ↗

Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping.Semantic proximity Read ↗

Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors.Semantic proximity Read ↗

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.Semantic proximity Read ↗

Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.Semantic proximity Read ↗

EGFR and tyrosine kinase inhibitor interactions probed by hydrogen-deuterium exchange and mass spectrometry (HDX-MS)Semantic proximity Read ↗

Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR InhibitorSemantic proximity Read ↗

Overcoming EGFR resistance by monovalent and bident inhibitors targeting Cys775Semantic proximity Read ↗

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.Semantic proximity Read ↗

Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.